For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity. The post The Role of Medication Delivery in Non-Adherence appeared first on MedCity News.
The answer to this question depends, not only on how well AI tools work, but also on how AI technologies are regulated by the FDA. Scott Gottlieb has some thoughts on preferred regulatory approaches in his recent article in JAMA Health Forum. Artificial intelligence tools with advanced analytical capabilities used in clinical practice, especially tools…
It’s been about two years since most states began receiving millions of dollars in opioid settlement payments from companies that made or distributed prescription painkillers. But whether you can track how that windfall has been spent depends largely on where you live. That’s because there is no federal standard dictating the information that must be…
Company supports patients throughout the surgical journey by coupling a smart phone app with a real-life health coach
Tufts University, Kaiser Permanente and several other healthcare organizations recently launched the Food is Medicine National Network of Excellence. The network aims to develop, assess and share the best practices in the food-is-medicine space. The post What Tufts, Kaiser Permanente and Others Hope to Achieve with the Food is Medicine National Network of Excellence appeared…
This technological shift not only boosts efficiency and profitability for pharmaceutical companies but also speeds up the delivery of innovative therapies to patients. The post Overcoming Pharma’s Major Pain Points and Pitfalls With AI appeared first on MedCity News.
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
Virtual care is no longer just a convenience, it is a necessity. The question is no longer whether virtual-first care is viable but how quickly we can make it the preferred model for modern healthcare. The post ViVE 2025: Shaping the Future of Virtual-first Care appeared first on MedCity News.
Perhaps this is what President Trump is exploring. Reuters reports: Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid by other developed countries, according to two company sources who called the option the pharmaceutical industry’s top concern.Both sources, who were not authorized to speak publicly, said…
LLMs, with their remarkable conversational abilities, are uniquely positioned to help solve this crisis. But as with the dotcom boom before it, the surge of AI ‘therapists’ has created a turbulent landscape where separating legitimate innovation from dangerous shortcuts isn’t straightforward. The post Patient-Facing AI: Separating Signal from Noise appeared first on MedCity News.